403 related articles for article (PubMed ID: 21739105)
21. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
22. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis.
Shi CG; Zhang Y; Yuan W
Am J Ther; 2016; 23(3):e894-904. PubMed ID: 25844482
[TBL] [Abstract][Full Text] [Related]
25. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
26. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Shah I; Johari A
Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
[TBL] [Abstract][Full Text] [Related]
27. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.
Bishop N; Harrison R; Ahmed F; Shaw N; Eastell R; Campbell M; Knowles E; Hill C; Hall C; Chapman S; Sprigg A; Rigby A
J Bone Miner Res; 2010 Jan; 25(1):32-40. PubMed ID: 19580461
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
29. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
30. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Takakuwa M; Iwamoto J; Itabashi K
Clin Drug Investig; 2012 Feb; 32(2):121-9. PubMed ID: 22185631
[TBL] [Abstract][Full Text] [Related]
31. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
32. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Watts NB; Geusens P; Barton IP; Felsenberg D
J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
[TBL] [Abstract][Full Text] [Related]
33. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
[TBL] [Abstract][Full Text] [Related]
34. Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
Sridharan K; Sivaramakrishnan G
Curr Clin Pharmacol; 2018; 13(3):190-198. PubMed ID: 30160216
[TBL] [Abstract][Full Text] [Related]
35. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Siris ES; Simon JA; Barton IP; McClung MR; Grauer A
Osteoporos Int; 2008 May; 19(5):681-6. PubMed ID: 17968610
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
McClung MR; Miller PD; Brown JP; Zanchetta J; Bolognese MA; Benhamou CL; Balske A; Burgio DE; Sarley J; McCullough LK; Recker RR
Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
[TBL] [Abstract][Full Text] [Related]
38. Fracture risk remains reduced one year after discontinuation of risedronate.
Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
[TBL] [Abstract][Full Text] [Related]
39. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
Folkestad L
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
